Sign inJoin waitlistJoin the waitlist

Paula Pohlmann

Chief, Section of Clinical Research and Drug Development, Breast Medical Oncology · University of Texas M D Anderson Cancer Center

Credentials: · · · · · · · ·

History

Section of Clinical Research and Drug Development · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Internal Medicine
Vanderbilt University Medical Center
2009–2011
Hematology and Medical Oncology
Vanderbilt University Medical Center
2006–2009
Vanderbilt University Medical Center
2005–2006
Medical Oncology
Medical Oncology
1995–1997
Hospital de Clínicas Porto Alegre
1993–1994
Doctor of Medicine
1988–1992

Research

Resistance to Trastuzumab in Breast Cancer
Clinical Cancer Research · 2009 · First of 3 authors · 394 citations
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Journal of Clinical Oncology · 2019 · 299 citations
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies
Cancer Cell · 2022 · 290 citations

Claudine Isaacs
28 papers
Hope Rugo
18 papers
Filipa Lynce
16 papers
Laura Esserman
15 papers
Rita Nanda
14 papers
Douglas Yee
13 papers
Angela DeMichele
12 papers
SS
Sandra Swain
11 papers
Kathy Albain
8 papers
ML
Minetta Liu
8 papers
William Symmans
8 papers
Amy Clark
7 papers

Clinical trials

PRE-ISPY Phase I/II Oncology Platform Program
Principal investigator · Recruiting · Phase 1, Phase 2
QuantumLeap Healthcare Collaborative
2023–2031
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
Principal investigator · Withdrawn · Phase 1
QuantumLeap Healthcare Collaborative
2021